Literature DB >> 33562114

The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.

Christoph M Janitzek1,2, Philip H R Carlsen1,2, Susan Thrane1,2, Vijansh M Khanna1,2, Virginie Jakob3, Christophe Barnier-Quer4, Nicolas Collin4, Thor G Theander1,2, Ali Salanti1,2, Morten A Nielsen1,2, Adam F Sander1,2.   

Abstract

Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. This study compared the humoral immune responses in mice elicited against two different vaccine antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six different adjuvant formulations. In comparison to antibody responses obtained after immunization with the unadjuvanted CLP vaccine, three of the adjuvant systems (neutral liposomes/monophosphoryl lipid A/quillaja saponaria 21, squalene-in-water emulsion, and monophosphoryl lipid A) caused significantly increased antibody levels, whereas formulation with the three other adjuvants (aluminum hydroxide, cationic liposomes, and cationic microparticles) resulted in similar or even decreased antibody responses. When delivering the soluble bacterial protein in a squalene-in-water emulsion, 4-log lower IgG levels were obtained compared to when the protein was delivered on CLPs without the adjuvant. The AP205 CLP platform promoted induction of both IgG1 and IgG2 subclasses, which could be skewed towards a higher production of IgG1 (aluminum hydroxide). Compared to other routes, intramuscular administration elicited the highest IgG levels. These results indicate that the effect of the external adjuvant does not always synergize with the adjuvant effect of the CLP display, which underscores the need for empirical testing of different extrinsic adjuvants.

Entities:  

Keywords:  AP205; adjuvants; capsid-like particle; route of immunization; vaccine; virus-like particle

Year:  2021        PMID: 33562114      PMCID: PMC7915698          DOI: 10.3390/vaccines9020131

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  75 in total

1.  Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses.

Authors:  Juliana Bessa; Andrea Jegerlehner; Heather J Hinton; Paul Pumpens; Philippe Saudan; Pascal Schneider; Martin F Bachmann
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

2.  The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses.

Authors:  Hideaki Kouzaki; Koji Iijima; Takao Kobayashi; Scott M O'Grady; Hirohito Kita
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

3.  Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway.

Authors:  Stephanie J Win; Vernon K Ward; P Rod Dunbar; Sarah L Young; Margaret A Baird
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

Review 4.  Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.

Authors:  Giuseppe Del Giudice; Rino Rappuoli; Arnaud M Didierlaurent
Journal:  Semin Immunol       Date:  2018-05-23       Impact factor: 11.130

5.  Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.

Authors:  Anja Seubert; Samuele Calabro; Laura Santini; Barbara Galli; Alessia Genovese; Sara Valentini; Susanna Aprea; Annalisa Colaprico; Ugo D'Oro; Marzia M Giuliani; Michele Pallaoro; Mariagrazia Pizza; Derek T O'Hagan; Andreas Wack; Rino Rappuoli; Ennio De Gregorio
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 6.  PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.

Authors:  A L Silva; P C Soema; B Slütter; F Ossendorp; W Jiskoot
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

7.  Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages.

Authors:  Alexander I Makarkov; Makan Golizeh; Elizabeth Ruiz-Lancheros; Angelica A Gopal; Ian N Costas-Cancelas; Sabrina Chierzi; Stephane Pillet; Nathalie Charland; Nathalie Landry; Isabelle Rouiller; Paul W Wiseman; Momar Ndao; Brian J Ward
Journal:  NPJ Vaccines       Date:  2019-05-15       Impact factor: 7.344

Review 8.  Virus-like particles for vaccination against cancer.

Authors:  Mona O Mohsen; Daniel E Speiser; Alexander Knuth; Martin F Bachmann
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-08-27

9.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

10.  Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

Authors:  Mark H Einstein; Peter Takacs; Archana Chatterjee; Rhoda S Sperling; Nahida Chakhtoura; Mark M Blatter; Jacob Lalezari; Marie-Pierre David; Lan Lin; Frank Struyf; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

View more
  1 in total

1.  Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of Leptospira Immunoglobulin-Like Protein A Subunit Vaccine.

Authors:  Teerasit Techawiwattanaboon; Thomas Courant; Livia Brunner; Suwitra Sathean-Anan-Kun; Pratomporn Krangvichian; Nutta Iadsee; Yaowarin Nakornpakdee; Noppadon Sangjun; Pat Komanee; Nicolas Collin; Kiat Ruxrungtham; Kanitha Patarakul
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.